Spero Therapeutics announces $5.9 million award from U.S. Department of Defense to further clinical development of SPR206
Tuesday, July 16, 2019 | DrugName : SPR-206 Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing
Read More